<DOC>
	<DOCNO>NCT02667496</DOCNO>
	<brief_summary>Primary Objective : To compare effect repeat dose Leukine placebo administer subcutaneously ( SC ) establish cortical amyloid load patient mild cognitive impairment ( MCI ) due Alzheimer 's disease ( AD ) . Secondary Objective : - To evaluate safety tolerability Leukine versus placebo . - To explore effect Leukine versus placebo cognitive performance . - To collect biospecimens future biomarker research .</brief_summary>
	<brief_title>Safety Study Sargramostim Treating Patients With Mild Cognitive Impairment Due Alzheimer 's Disease</brief_title>
	<detailed_description>The total duration study period per patient 28 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Inclusion criterion : Men woman ≥40 year ≤80 year diagnosis MCI due AD accord National Institutes Aging Alzheimer 's Association ( NIAAA ) criterion ( intermediate high likelihood ) sporadic familial inheritance pattern . Mild cognitive impairment AD define : Evidence concern change cognition , comparison person 's previous level ( subjective memory complaint/decline past year 6 month and/or confirm informant and/or clinician ) , Objective impairment memory function document error score delay recall section Alzheimer 's Disease Assessment Scalecognitive subscale ( ADAScog ) ≥1.5 standard deviation ( SD ) agestratified mean ; ie , Age 5569 year : ≥6 error Age 7074 year : ≥7 error Age 75+ year : ≥8 error But definite impairment ( ) activity daily live ( ADLs ) , Investigator 's view assess Alzheimer 's Disease Cooperative Study ( ADCS ) ADL adapt MCI , Evidence elevate cortical amyloid positron emission tomography ( PET ) use florbetapir F18 ( Amyvid ) ( positive scan ) qualitative assessment accord product label . Have dedicate partner/caregiver informant assist patient study procedure administration study medication , company patient least 12 hour week . Willing able provide sign informed consent . Exclusion criterion : Any technical/administrative reason make impossible randomize patient study . Prior treatment investigational antiamyloid therapy . Contraindication lumbar puncture , contraindication inability complete magnetic resonance imaging ( MRI ) past plan exposure ionize radiation would , together radiation result administration PET tracer use study , exceed applicable institutional , local , national recommendation annual lifetime exposure . Modified Hachinski Ischemic Score &gt; 4 . Other neurological psychiatric condition ( AD ) impair cognition ; , computerize tomography ( CT ) /MRI evidence potentially significant intracranial abnormality relate AD ( eg , evidence major stroke lacune area critical cognition , infection , cancer , hydrocephalus , multiple sclerosis etc . ) ; abnormal cerebrospinal fluid ( CSF ) consistent AD . MRI evidence &gt; 4 microhemorrhages : patient may prone spontaneous amyloidrelated imaging abnormality ( ARIAH ) and/or may susceptible adverse effect ARIAH . Untreated unstable medical condition could interfere study assessment opinion Investigator may require immunestimulating , immunesuppressive , immunemodulating treatment ( ) conduct study ; eg , immunoglobulin , therapeutic vaccine , cytokine , anticytokine monoclonal antibody . History asplenia , hyposplenia , splenectomy ( whatever surgical reason ) . Current mood anxiety disorder , and/or psychotic disorder , and/or substancerelated disorder accord Diagnostic Statistical Manual Psychiatric Disorders , Edition IV , text revision ( DSMIVTR ) DSMV ; consider suicidal show suicidal ideation assess Investigator . Laboratory abnormality indicative untreated medical hematologic condition could increase risk interfere study assessment include untreated hypo hyperthyroidism , vitamin B12 deficiency , hyperleukocytic syndrome ( include restrict chronic myelogenous leukemia , Hodgkin nonHodgkin lymphoma ) , monoclonal gammopathy , thrombocythemia . Known renal dysfunction serum creatinine &gt; 150 µmol/L . Known hepatic dysfunction ( apart Gilbert 's syndrome ) serum alanine aminotransferase ( ALT ) ≥3 time upper limit normal ( ULN ) . Pregnant breastfeed woman . Presence history drug hypersensitivity ; know hypersensitivity sargramostim , yeastderived product , component product , benzyl alcohol ( present bacteriostatic water saline infusion ) . Evidence fluid retention ( clinical radiological ) , respiratory symptom ( eg , dyspnea ) , cardiovascular symptom electrocardiographic evidence cardiac disease warrant therapeutic intervention ( eg , supraventricular arrhythmia ) . History deep vein thrombosis ( DVT ) pulmonary embolism familial predisposition DVT pulmonary embolism . Women female partner childbearing potential protect highly effective contraceptive method birth control ( ie , oral depot contraceptive intrauterine device [ IUD ] subject surgically sterilize ) and/or unwilling unable tested pregnancy ; pregnant lactating . Recipient investigational drug within prior 60 day , within 5 time elimination halflife drug , whichever long . History latex allergy yeast allergy . Any patient : Is likely noncompliant , leave area , separate designate caregiver/informant 3 day study , Unable cooperate language problem poor mental development , Oversees implement aspect study , Is employ Sanofi affiliate subsidiary ( eg , Genzyme , SanofiPasteur , Merial ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>